The FDA's September 14, 2026 hearing gathered input on the future therapeutic use of psychedelic drugs. It approved nothing and changed no schedule.
The FDA held a public hearing on psychedelic drugs on September 14, 2026, to collect input on the potential future therapeutic use of psychedelic drug products in supervised and supportive settings. At The Psychedelic Journal, we conducted a desk review of the published Federal Register notice and agency event materials on October 16, 2026, to examine the scope of this proceeding.
The hearing was an information-gathering session under 21 CFR part 15. It did not approve any medical treatment, reclassify any controlled substance, or alter federal scheduling.
The FDA psychedelic public hearing on September 14, 2026, was a four-hour federal information-gathering meeting held to obtain public feedback on issues associated with the potential future therapeutic use of psychedelic drugs. Convened in collaboration with federal partner agencies, the session ran from 12:30 p.m. to 4:30 p.m. Eastern Time. The agency conducted the event in a hybrid format, pairing virtual participation with an in-person meeting at the FDA White Oak Campus Great Room in Silver Spring, Maryland.
The FDA organized the proceeding under 21 CFR part 15, a provision of FDA regulations for public hearings. The agency assigned the proceeding Docket No. FDA-2026-N-7542, titled "Considerations for Potential Future Therapeutic Use of Psychedelic Drugs; Public Hearing; Request for Comments." The formal notice was scheduled for publication in the Federal Register on July 14, 2026, under document number 2026-14155.
Participation requirements were set in advance of the session. Registration, including requests to present, closed on August 21, 2026, and the FDA's event page said the hearing could be viewed live on its YouTube channel. The meeting provided a forum for public stakeholders to submit perspectives, but it did not function as an approval committee.
The FDA psychedelic public hearing did not change the legal status of any substance, grant marketing approval to any drug product, or reschedule any compound under federal law. The agency stated in its notice that holding the hearing was not intended to suggest regulatory action outside statutory authority. The notice also highlighted that several related policy areas implicate the legal authorities of other federal agencies or individual states.
Federal scheduling remains unchanged following the session. Psilocybin, LSD, and MDMA remain Schedule I substances under the federal Controlled Substances Act, and state programs that allow them operate under state law, not as federal approval. See our guide to legal psychedelics in the U.S. for broader context.
The notice also clarified that a voucher or designation is not regulatory clearance. Neither the issuance of a national priority voucher nor the granting of Breakthrough Therapy designation represents an FDA finding of safety or effectiveness. Neither mechanism serves as a substitute for formal marketing approval.
The FDA structured its request for comments around four areas: provider training, patient safety, access models, and data collection systems. The first topic, provider training and credentialing, focused on the evidence base for training curricula and the expert bodies that could develop or endorse them. The agency invited perspectives on staffing needs across distinct phases of care, including screening, administration, and follow-up. This inquiry covered minimum staffing levels during drug administration, credentialing standards, supervision requirements, and the specific roles of non-prescriber personnel such as licensed counselors and peer support specialists. See also how to become a psychedelic therapist.
The second topic addressed the promotion of patient safety inside supervised settings. The FDA asked for best practices in patient education, set and setting assessment, and informed consent. Consent considerations included the risk of psychological distress, the therapeutic use of touch, and the potential for an amplified power imbalance between patients and providers. The agency also highlighted the need for screening criteria for conditions carrying greater medical risk, naming cardiovascular disease, psychosis, and suicidality. Additional safety topics included practitioner oversight mechanisms, post-administration crisis response coordination, and diversion prevention strategies for approved drug products.
The third topic covered access considerations and healthcare delivery logistics. The agency sought evidence regarding insurance coverage, benefit design, reimbursement frameworks, and health economic impact analyses. The notice also asked about practical clinic capacity, including facility space, drug storage, security protocols, and appointment scheduling. See also psychedelic therapy for veterans. The inquiry requested feedback on the role of telehealth in conducting initial patient screening, follow-up evaluations, and ongoing care coordination.
The fourth topic examined best practices for data collection and standardization. The FDA requested input on establishing data repositories, such as Coordinated Registry Networks, to track patient outcomes over time. The agency asked how to link multiple existing data streams, including electronic health records, insurance claims, registries, pharmacy data, and adverse event reports. This topic also focused on creating common data elements, standardizing adverse event definitions, and managing patient privacy across longitudinal follow-up registries.
The FDA explicitly excluded five subject areas from the hearing scope, advising participants that submissions on these topics might not be considered. First, the agency stated it would not accept comments evaluating the safety or effectiveness of any particular drug product, nor the merits of any pending or anticipated drug application.
Second, the agency excluded the scheduling status of any substance under the Controlled Substances Act, pointing out that drug classification is governed by separate statutory procedures. Third, the FDA stated it was not seeking comment on the legalization or decriminalization of psychedelic substances, nor on the merits of state or local programs that authorize their use. However, the agency noted it welcomed input on data collection from those existing programs.
Fourth, the notice excluded discussions of religious, ceremonial, or personal non-medical psychedelic use. Fifth, the agency said it was not seeking comment on individual disputes, enforcement matters, or complaints regarding individual practitioners or commercial entities. The notice states that comments and presentations on these excluded topics may not be considered.
The FDA notice cited several prior federal administrative actions and regulatory designations as background for the public hearing. The notice states the hearing supports implementation of Executive Order 14401 of April 18, 2026, titled "Accelerating Medical Treatments for Serious Mental Illness" (published at 91 FR 21709 on April 22, 2026). This executive directive established a policy to accelerate innovative research and appropriate drug approvals for serious mental illness, instructing the Department of Health and Human Services and the FDA to collaborate with partner agencies on trial participation, data sharing, and real-world evidence models. See our guide to the executive order on psychedelics.
The notice also cited previous priority voucher actions. In April 2026, the FDA issued national priority vouchers to corporate sponsors evaluating psilocybin for treatment-resistant depression, psilocybin for major depressive disorder, and methylone for post-traumatic stress disorder. According to the notice, these vouchers are intended to shorten application review periods for qualifying submissions while maintaining scientific evaluation standards.
The agency pointed to past Breakthrough Therapy designations awarded to psychedelic development programs. These historical designations include MDMA for post-traumatic stress disorder, granted to the Multidisciplinary Association for Psychedelic Studies in 2017, and psilocybin for treatment-resistant depression, granted to COMPASS Pathways in 2018. The agency also cited a 2019 Breakthrough Therapy designation for psilocybin in major depressive disorder. As emphasized in the notice, these administrative designations do not constitute marketing approvals.
Public participation for the FDA psychedelic public hearing ran through written comments on Docket No. FDA-2026-N-7542. The agency accepted written electronic comments submitted through the Federal eRulemaking Portal at regulations.gov until 11:59 p.m. Eastern Time on October 5, 2026. The official notice stated that comments received after that cut-off date will not be considered by the agency.
As of October 16, 2026, the public comment period is officially closed. Under the notice, timely comments are placed in the docket and, unless submitted as confidential, are publicly viewable; we did not check the docket itself. Meeting materials, including the official agenda and the public commenter roster, are posted through the FDA meeting event page.
Our review is based entirely on the Federal Register notice and the agency event page. We did not review meeting transcripts or the individual comments filed in the docket. We found nothing in the two documents reviewed saying when or whether the FDA may act on the comments or what it may do after the docket closed.
The notice does not change federal scheduling, and we checked no state's law for this page. The FDA notice lists state programs for psychedelic use as one of several data sources and welcomes input on data collection from them, while saying it is not seeking comment on their merits. State programs operate under state law, not federal approval. See our guide to Colorado natural medicine rulemaking.
This page makes no individualized state legal determinations. You can use our state-by-state legal status tool to review local rules. This page contains no dosing protocols, preparation guidelines, product sourcing advice, or treatment-access instructions.
To review the regulatory materials for the hearing, consult the official Federal Register notice or examine the submitted docket records on regulations.gov.
The FDA psychedelic public hearing was an administrative proceeding under 21 CFR part 15 held to collect public feedback on the potential future therapeutic use of psychedelic drugs in supervised settings. Convened with federal partners, the hearing focused on provider credentialing, patient safety, treatment access, and data collection standards. It was an information-gathering meeting rather than an approval decision.
The hearing took place on September 14, 2026, from 12:30 p.m. to 4:30 p.m. Eastern Time. It operated in a hybrid format, offering virtual access alongside an in-person session at the FDA White Oak Campus in Silver Spring, Maryland. Advance registration to present closed on August 21, 2026.
No. The hearing did not legalize or decriminalize any psychedelic substance. The FDA explicitly stated in its notice that broad legalization, decriminalization, and Controlled Substances Act rescheduling were excluded from the topics open for comment. Federal drug classifications remain unchanged.
No. The formal public comment period for Docket No. FDA-2026-N-7542 closed at 11:59 p.m. Eastern Time on October 5, 2026. The agency stated in its notice that submissions received after that deadline will not be considered.
No. The public hearing was not an approval session, and nothing in the notice approves a psychedelic drug. The agency specifically noted that the safety, effectiveness, or merits of individual pending drug products were excluded from the scope of the hearing.
We checked no state's law for this page, and the notice does not change federal scheduling. State programs operate under state law, not federal approval. The FDA welcomed input on data collection from state programs but said it was not seeking comment on their merits.
Get psilocybin research & policy updates
New trials, FDA decisions, and legal changes for psilocybin — delivered when they happen.
Suggest a tool, topic, or improvement that would make this site more useful.